Notification, regarding mandatory acquisition of shares

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
127
Notification, regarding mandatory acquisition of shares

AB “Vilniaus degtinė” (ISIN code LT0000112450, Panerių str. 47, Vilnius, Lithuania, company code 120057287) (hereinafter – the Company), received notification from its main shareholder Marie Brizard Wine & Spirits, that it will implement mandatory acquisition of AB “Vilniaus degtinė” shares, exercising its rights stated in article No. 42 of Law on Securities of Lithuanian Republic. Due to this fact and following part No. 8 of article No. 42 of Law on Securities, AB “Vilniaus degtinė” is submitting this notification.

Legal person performing mandatory acquisition os shares - Marie Brizard Wine & Spirits (40 Quai Jean Compagnon et 19 Bd Paul Vaillant Couturier 94200 Ivry-sur-Seine, France) (hereinafter – MBWS) acting together with Marie Brizard Wine & Spirits Polska sp z o o (Krakowiaków 48, 02-255, Warsaw, Poland) (hereinafter – MBWS Polska).

MBWS, owns  23 880 434 shares of AB “Vilniaus degtinė”, which is 97,84% (i.e. more than 95%) of all shares of AB “Vilniaus degtinė” (of which 29,55% MBWS owns directly and 68,29% through MBWS Polska) and owns 97,84% of voting rights in the general meeting of shareholders of the Company (according to data as of 9th of January, 2017).

MBWS demands, that all the remaining shareholders of the Company would sell shares of AB “Vilniaus degtinė” owned by them during 90 days from publishing notification about mandatory acquisition of the shares in VĮ Registrų centras issued electronic journal “Public announcement of legal entities”. Such notification will be published on 11th of January, 2017, due to this term for selling shares will end on 11th of April, 2017 (this will be the last day to sell shares). During this term shareholders has the right to contest price offered for the shares, according to procedures stated by Article 42 Part 13 of the Law on Securities.

For one ordinary registered share of the Company MBWS offers 0,432 EUR. The Price for shares of the Company is established in accordance with the Article 42 part 4 and Article 39 of the Law on Securities of the Republic of Lithuania – the price is the same which was paid during the mandatory tender offer. Price of mandatory acquisition of the shares is Approved by decision of Supervision Office Director, of Bank of Lithuania of 9th of January, 2017 No. 241-3.

Mandatory acquisition of shares MBWS will perform through AB Šiaulių bankas, in which MBWS will place an order to the market to buy the remaining shares of the Company, which shall be valid for 90 (ninety) days after the public notification about the mandatory acquisition, which will be published in VĮ Registrų centras issued electronic journal “Public announcement of legal entities” (that is from 11th of January, 2017 till 11th of April, 2017). Settlement for the shares shall be made in cash – T+2 (in the second day after the execution of the transaction). The shares can be sold at any day during the announced mandatory sale of shares. If any of the shareholders fail to sell their shares, MBWS shall request that the shares of the Company which were not sold would be recorded to the securities account of MBWS, i.e. that would be made records regarding the transfer of ownership to the shares to MBWS. Settlement for such shares shall be performed after the ruling of the court comes into effect, from the money which shall be deposited at the special account. Each shareholder which will not sell its shares shall be notified about this separately. 

Any shareholder of the Company may find the documents (that were the basis of setting the price for the shares) in the Company during the working hours of the Company. 

Attached: MBWS notification about mandatory acquisition of the shares

General Manager

Dovilė Tamoševičienė

852330819

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading